U.S., April 9 -- ClinicalTrials.gov registry received information related to the study (NCT07517744) titled 'Comparison Between Darbapoeitin Alpha and Roxadustat in CKD-related Anemia' on April 02.
Brief Summary: Anemia is a common and debilitating complication of end-stage kidney disease (ESKD) that is associated with reduced quality of life and high morbidity and mortality. ESKD-related anemia is associated with many adverse comorbidities and outcomes; however, normalizing the levels of hemoglobin proved to be insignificant in improving most adverse outcomes. This study aims to evaluate the real-world effectiveness and safety of an ESA and a HIF-PHI in patients with CKD-related anemia.
Study Start Date: June 01, 2024
Study Type: OBSERV...